Seeking Alpha

Sarepta Therapeutics (SRPT) says eteplirsen (I, II) continues to show promise in improving the...

Sarepta Therapeutics (SRPT) says eteplirsen (I, II) continues to show promise in improving the walking ability of Duchenne muscular dystrophy patients after 84 weeks. Shares +4% premarket. (PR)
Comments (1)
  • whaddyamean?
    , contributor
    Comments (514) | Send Message
     
    "Continues to show promise" results in a 4% premarket pop?

     

    Now that I've done my due diligence, it's time to pull the trigger!

     

    Don't you just love these biotechs?
    19 Jun 2013, 09:03 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector